NVP 1402Alternative Names: NVP-1402
Latest Information Update: 21 Sep 2016
At a glance
- Originator Navipharm
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 07 Sep 2016 Navipharm Corporation plans a phase I pharmacokinetics trial in Healthy volunteers in South Korea (PO) (NCT02897726)
- 03 Aug 2016 Preclinical trials in CNS disorders in South Korea (PO)